1191995-00-2CC(C)C[C@@H](C(=O)Nc1ccn(C[C@@H](O)CO)n1)N1CC(Oc2ccccc2Cl)=CC1=OHMUMWSORCUWQJO-QAPCUYQASA-NDorzagliatin is a secondary carboxamide resulting from the formal condensation of the carboxy group of (2S)-2-[4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl]-4-methylpentanoic acid with the amino group of (2R)-3-(3-amino-1H-pyrrol-1-yl)propane-1,2-diol. It is an allosteric glucokinase activator developed by Hua Medicine for the treatment of type 1 and 2 diabetes mellitus , and diabetic kidney disease. It has a role as an enzyme activator and a hypoglycemic agent. It is a secondary carboxamide, a primary alcohol, a pyrroline, a diol, a member of pyrazoles, an aromatic ether, a secondary alcohol, a tertiary amino compound, an enone and a member of monochlorobenzenes.
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
BeschreibungDorzagliatin (trade name HuaTangNing) is a first-in-class small molecule oral glucokinase activator (GKA) developed by Hua Medicine for the treatment of diabetic nephropathy (DKD), type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Dorzagliatin was first approved in China in September 2022 as a monotherapy or in combination with metformin, an antidiabetic drug, for adults with type 2 diabetes.
Wird geladen…
1191995-00-2CHEMBL4297508CHEBI:234514